Published May 2018
| Accepted Version + Submitted + Supplemental Material
Journal Article
Open
Photoactivatable drugs for nicotinic optopharmacology
- Creators
- Banala, Sambashiva
-
Arvin, Matthew C.
- Bannon, Nicholas M.
- Jin, Xiao-Tao
- Macklin, John J.
-
Wang, Yong
- Peng, Can
- Zhao, Guiqing
- Marshall, John J.
- Gee, Kyle R.
- Wokosin, David L.
- Kim, Veronica J.
- McIntosh, J. Michael
- Contractor, Anis
-
Lester, Henry A.
-
Kozorovitskiy, Yevgenia
-
Drenan, Ryan M.
-
Lavis, Luke D.
Chicago
An error occurred while generating the citation.
Abstract
Photoactivatable pharmacological agents have revolutionized neuroscience, but the palette of available compounds is limited. We describe a general method for caging tertiary amines by using a stable quaternary ammonium linkage that elicits a red shift in the activation wavelength. We prepared a photoactivatable nicotine (PA-Nic), uncageable via one- or two-photon excitation, that is useful to study nicotinic acetylcholine receptors (nAChRs) in different experimental preparations and spatiotemporal scales.
Additional Information
© 2018 Macmillan Publishers Limited, part of Springer Nature. Received: 26 September 2017; Accepted: 26 February 2018; Published: 26 March 2018. Data availability. The data that support the findings of this study, if not explicitly contained within the text, supplementary figures, or Supplementary Note 1, are available from the corresponding authors upon reasonable request. Source data for Figures 1 and 2 and Supplementary Figures 1–6 are available online. We thank members of the Drenan and Lavis laboratories for helpful advice and discussion, and T. Lerner (Northwestern University, Chicago, Illinois, USA) for contributing viral reagents. This work was supported by the Howard Hughes Medical Institute (to S.B., J.J.M., and L.D.L.), the US National Institutes of Health (NIH) (grants DA035942 and DA040626 to R.M.D., MH099114 to A.C., DA037161 to H.A.L., NS054850 to D.J. Surmeier, and GM103801 and GM48677 to J.M.M.), the PhRMA Foundation (fellowship to M.C.A.), the Arnold and Mabel Beckman Foundation (Beckman Young Investigator Award to Y.K.), the Bernice E. Bumpus Foundation (Early Career Innovation Award to Y.K.), the Rita Allen Foundation (to Y.K.), the Searle Scholars Program (to Y.K.), the Alfred P. Sloan Foundation (Sloan Research Fellowship to Y.K.), NINDS (grant NINDS F32 NS103243 to N.M.B.), the JPB Foundation, and Northwestern University. Author Contributions: R.M.D., M.C.A., H.A.L., S.B., K.R.G., and L.D.L. conceived the project. M.C.A., N.M.B., D.L.W., X.-T.J., J.J.M., Y.W., C.P., G.Z., V.J.K., J.J.M., A.C., Y.K., R.M.D., S.B., and L.D.L. planned and/or executed experiments. D.L.W., Y.K., J.M.M., and K.R.G. contributed essential reagents and expertise. R.M.D., M.C.A., S.B., and L.D.L. wrote the paper with input from all other authors. R.M.D. and L.D.L. supervised all aspects of the work. Competing interests: K.R.G. is an employee of Thermo Fisher Scientific and has stock options. All other authors declare no competing interests.Attached Files
Accepted Version - nihms947829.pdf
Submitted - 260232.full.pdf
Supplemental Material - nmeth.4637-S1.pdf
Supplemental Material - nmeth.4637-S2.pdf
Files
260232.full.pdf
Additional details
- Alternative title
- Development of photoactivatable drugs enables nicotinic optopharmacology
- PMCID
- PMC5923430
- Eprint ID
- 85557
- Resolver ID
- CaltechAUTHORS:20180402-095419703
- Howard Hughes Medical Institute (HHMI)
- NIH
- DA035942
- NIH
- DA040626
- NIH
- MH099114
- NIH
- DA037161
- NIH
- NS054850
- NIH
- GM103801
- NIH
- GM48677
- PhRMA Foundation
- Arnold and Mabel Beckman Foundation
- Bernice E. Bumpus Foundation
- Rita Allen Foundation
- Searle Scholars Program
- Alfred P. Sloan Foundation
- NIH
- F32 NS103243
- JPB Foundation
- Northwestern University
- Created
-
2018-04-02Created from EPrint's datestamp field
- Updated
-
2023-06-01Created from EPrint's last_modified field